About the Program
This case-based program was developed by the Canadian Neurological Science Federation and includes 1 module with 20 questions.
Estimated completion time: 2.0 hours. Complete the program at your pace by saving your progress at any time.
Planning Committee
- Dr. Santanu Chakraborty, Neuroradiologist, Ottawa (ON)
- Dr. Rafael Glikstein, Neuroradiologist, Ottawa (ON)
- Dr. Alex Henri-Bhargava, Neurologist, Victoria (BC)
- Dr. Andrew Kirk, Neurologist, Saskatoon (SK)
- Dr. Sara Mitchell, Neurologist, Toronto (ON)
Learning Objectives
This activity will allow participants to:
- Use clinical tools to assess signs and symptoms for diagnosis of Alzheimer's disease (AD).
- Assess the role of different biomarkers in the detection and diagnosis of AD.
- Interpret neuroimaging findings to detect structural abnormalities associated with AD.
- Explain the use of nonpharmacological and symptomatic interventions for AD.
- Discuss the status of emerging disease-modifying therapies (DMTs) and identify potential associated adverse events such as amyloid-related imaging abnormalities – edema/effusion (ARIA-E) and amyloid-related imaging abnormalities – hemorrhagic (ARIA-H).
- Explain how and when to monitor disease progression and determine the next steps in clinical management.
Key Features
- Case-Based Learning: Increase your knowledge through a case-based scenario, including diagnosis, disease progression, patient monitoring, non-pharmacological interventions, neuroimaging, and treatment options, including novel disease-modifying therapies.
- Test Your Knowledge: Assess your understanding with knowledge and practice-based questions. Receive immediate feedback tailored to your answers, and links to resources and guidelines to further solidify your learnings.
- Flexible and convenient: Pause and resume at your pace, save your progress, and continue at a later time.
- Certification: Complete the program and the evaluation form to receive your certificate of completion and a detailed report of your answers.